Publikationen

British Journal of Haematology 137 (4): 297-306 (2007-05)

Westermann J.; Kopp J.; van Lessen A.; Hecker A.C.; Baskaynak G.; le Coutre P.; Doehner K.; Doehner H.; Doerken B.; Pezzutto A.

Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia

Description:
In chronic myeloid leukaemia (CML), dendritic cells (DC) and leukaemic cells share a common progeny, leading to constitutive expression of putative tumour antigens, such as bcr/abl, in DC. In this phase-I/II study, autologous DC were used as a vaccine in patients with chronic phase bcr/abl+ CML, who had not achieved an adequate cytogenetic response after treatment with alpha-interferon or imatinib. Ten patients were enrolled, DC were generated from peripheral blood monocytes and vaccination consisted of four subcutaneous injections of increasing numbers of DC (1-50 x 10(6) cells per injection) on days 1, 2, 8 and 21. Vaccination was feasible and safe. Improvement of the cytogenetic/molecular response, as detected by fluorescence in situ hybridization of peripheral blood mononuclear cells (PBMC), was possibly related to vaccination in four of 10 patients. In three of these patients, T cells recognizing leukaemia-associated antigens became detectable. The proliferative capacity of PBMC in response to autologous DC increased after vaccination in all evaluable patients. We conclude that vaccination with autologous, non-irradiated leukaemic DC is feasible, safe and induces anti-leukaemic T-cell responses in some CML patients. DC vaccination might be useful in CML as postremission therapy, i.e. after treatment with tyrosine kinase inhibitors.

Keywords: bcr/abl, T-cell immunity, Chronic myeloid leukaemia, Dendritic cells, Vaccination

Type: Article

PubMed: 17408402
Official URL: https://doi.org/10.1111/j.1365-2141.2007.06547.x
MDC Repository: https://edoc.mdc-berlin.de/8803/